Yang Jing, Hu Huazhong, Zhang Shuqin, Jiang Linrui, Cheng Yuanxiong, Xie Haojun, Wang Xiaoyan, Jiang Jiaohua, Wang Hong, Zhang Qun
Office of National Clinical Trials of Drugs, Guangzhou 510000, China.
Department of Respiratory and Critical Care Medicine, Guangzhou 510000, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jul 30;40(7):988-994. doi: 10.12122/j.issn.1673-4254.2020.07.11.
To study the anti- fibrotic effect of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-EXOs) and explore the mechanism.
Twenty-four C57 BL/6 mice were divided into 4 groups (=6), including the control group treated with intratracheal injection of saline (3 mg/kg); lung fibrosis model group with intratracheal injection of 1.5 mg/mL bleomycin solution (prepared with saline, 3 mg/kg); EXOs1 group with intratracheal injection of 1.5 mg/mL bleomycin solution (3 mg/kg) and hUCMSC-EXOs (100 μg/250 μL, given by tail vein injection on the next day after modeling); and EXOs2 group with intratracheal injection of 1.5 mg/mL bleomycin solution (3 mg/kg) and hUCMSC-EXOs (100 μg/250 μL, given by tail vein injection on the 10th day after modeling). At 21 days after modeling, pulmonary index, lung tissue pathology and collagen deposition in the mice were assessed using HE staining and Masson staining. The expression level of TGF-β1 was detected using ELISA, and vimentin, E-cadherin and phosphorylated Smad2/3 (p-Smad2/3) were detected using immunohistochemical staining. CCK8 assay was used to evaluate the effect of hUCMSCEXOs on the viability of A549 cells, and Western blotting was used to detect the expression levels of p-Smad2/3, vimentin, and E-cadherin in the cells.
Compared with those in the model group, the mice treated with hUCMSC-EXOs showed significantly reduced the pulmonary index ( < 0.05), collagen deposition, lung tissue pathologies, lowered expressions of TGF-β1 ( < 0.05), vimentin, and p-Smad2/3 and increased expression of E-cadherin. hUCMSC-EXOs given on the second day produced more pronounced effect than that given on the 11th day ( < 0.05). CCK8 assay results showed that hUCMSC-EXOs had no toxic effects on A549 cells ( > 0.05). Western blotting results showed that hUCMSC-EXOs treatment significantly increased the expression of E-cadherin and decreased the expressions of p-Smad2/3 and vimentin in the cells.
hUCMSC-EXOs can alleviate pulmonary fibrosis in mice by inhibiting epithelialmesenchymal transition activated by the TGF-β1/Smad2/3 signaling pathway, and the inhibitory effect is more obvious when it is administered on the second day after modeling.
研究人脐带间充质干细胞来源的外泌体(hUCMSC-EXOs)的抗纤维化作用并探讨其机制。
将24只C57 BL/6小鼠分为4组(每组n = 6),包括经气管内注射生理盐水(3 mg/kg)的对照组;经气管内注射1.5 mg/mL博来霉素溶液(用生理盐水配制,3 mg/kg)的肺纤维化模型组;经气管内注射1.5 mg/mL博来霉素溶液(3 mg/kg)并于建模后次日经尾静脉注射hUCMSC-EXOs(100 μg/250 μL)的EXOs1组;以及经气管内注射1.5 mg/mL博来霉素溶液(3 mg/kg)并于建模后第10天经尾静脉注射hUCMSC-EXOs(100 μg/250 μL)的EXOs2组。建模后21天,采用HE染色和Masson染色评估小鼠的肺指数、肺组织病理学及胶原沉积情况。采用ELISA检测TGF-β1的表达水平,采用免疫组织化学染色检测波形蛋白、E-钙黏蛋白和磷酸化Smad2/3(p-Smad2/3)。采用CCK8法评估hUCMSC-EXOs对A549细胞活力的影响,采用蛋白质免疫印迹法检测细胞中p-Smad2/3、波形蛋白和E-钙黏蛋白的表达水平。
与模型组相比,接受hUCMSC-EXOs治疗的小鼠肺指数显著降低(P < 0.05),胶原沉积、肺组织病理学改变减轻,TGF-β1(P < 0.05)、波形蛋白和p-Smad2/3表达降低,E-钙黏蛋白表达增加。建模后第二天给予hUCMSC-EXOs的效果比第11天给予的更显著(P < 0.05)。CCK8法检测结果显示hUCMSC-EXOs对A549细胞无毒性作用(P > 0.05)。蛋白质免疫印迹法检测结果显示,hUCMSC-EXOs处理显著增加细胞中E-钙黏蛋白的表达,降低p-Smad2/3和波形蛋白的表达。
hUCMSC-EXOs可通过抑制TGF-β1/Smad2/3信号通路激活的上皮-间质转化来减轻小鼠肺纤维化,且在建模后第二天给药时抑制作用更明显。